Clofazimine

規格

2030-63-9CAS番号

217-980-2EC番号

N,5-bis(4-chlorophenyl)-3-propan-2-yliminophenazin-2-amineIUPAC名

C27H22Cl2N4化学式

473.4 g/mol分子量

clofazimine; 2030-63-9; Lamprene; Chlofazimine; Clofazimina; Clofaziminum; NSC-141046; N,5-bis(4-chlorophenyl)-3-propan-2-yliminophenazin-2-amine; G 30320; DTXSID7022839; Colfazimine; G-30320; 3-(p-Chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin; D959AE5USF; 3-(p-Chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)-phenazine; NSC141046; g30320; B663; 2-Phenazinamine, 3,5-dihydro-N,5-bis(4-chlorophenyl)-3-((1-methylethyl)imino)-; 2-Phenazinamine, N,5-bis(4-chlorophenyl)-3,5-dihydro-3-((1-methylethyl)imino)-; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-[(1-methylethyl)imino]-2-phenazinamine; Phenazine, 3-(p-chloroanilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)-; CHEBI:3749; 2-Phenazinamine, N,5-bis(4-chlorophenyl)-3,5-dihydro-3-[(1-methylethyl)imino]-; N,5-bis(4-chlorophenyl)-3-(propan-2-ylimino)-3,5-dihydrophenazin-2-amine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-((1-methylethyl)imino)-2-phenazinamine; RefChem:57185; G30,320; G 30,320; J04BA01; DTXCID301064997; 217-980-2; Lampren; B 663 (Pharmaceutical); Clofaziminum [INN-Latin]; Clofazimina [INN-Spanish]; B-663; 3-(p-Chloroanilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine; B 663; MFCD00056793; N,5-bis(4-chlorophenyl)-3-(isopropylimino)-3,5-dihydrophenazin-2-amine; CHEMBL1083384; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-(isopropylimino)phenazin-2-amine; MMV687800; Phenazine, 2,10-dihydro-3-(p-chloroanilino)-10-(p-chlorophenyl)-2-(isopropylimino)-; NCGC00016600-01; CAS-2030-63-9; C27H22Cl2N4; N,5-bis(4-chlorophenyl)-3-[(propan-2-yl)imino]-3,5-dihydrophenazin-2-amine; 3-(p-Chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine; Riminophenazine; B 663 (VAN); Lamprene (TN); SMR000058704; B 663, pharmaceutical; SR-05000001807; EINECS 217-980-2; UNII-D959AE5USF; NSC 141046; BRN 0060420; Clofazimine (JAN/USP/INN); (3E)-N,5-bis(4-chlorophenyl)-3-isopropylimino-phenazin-2-amine; Clofazimine RS; Clofazimine CRS; WDQPAMHFFCXSNU-UHFFFAOYSA-N; Clofazimine [USAN:USP:INN:BAN]; Prestwick_685; 3-(p-Chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin [German]; SMP2_000339; Clofazimine (Standard); CPD000058704; CLOFAZIMINE [MI]; Prestwick0_000376; Prestwick1_000376; Prestwick2_000376; Prestwick3_000376; CLOFAZIMINE [INN]; CLOFAZIMINE [JAN]; CLOFAZIMINE [USAN]; B. 663; CLOFAZIMINE [VANDF]; COLFAZIMINE [VANDF]; cid_2794; CHEMBL1292; CLOFAZIMINE [MART.]; BIDD:PXR0147; SCHEMBL26757; SCHEMBL26758; BSPBio_000531; CLOFAZIMINE [USP-RS]; CLOFAZIMINE [WHO-DD]; CLOFAZIMINE [WHO-IP]; 4-25-00-03033 (Beilstein Handbook Reference); MLS000028617; MLS001424318; MLS006010789; SPBio_002452; BPBio1_000585; DTXCID302839; GTPL9184; orb1225740; orb1310671; orb3141362; SCHEMBL5663361; SCHEMBL29370522; SCHEMBL29373918; HY-B1046R; CLOFAZIMINE [ORANGE BOOK]; N,5-bis(4-chlorophenyl)-3-isopropylimino-phenazin-2-amine; WDQPAMHFFCXSNU-KRUMMXJUSA-N; CLOFAZIMINE [EP MONOGRAPH]; CLOFAZIMINE [USP IMPURITY]; GLXC-06907; HMS1569K13; HMS2052B05; HMS2093J10; HMS2096K13; HMS2231B04; HMS3370N05; HMS3394B05; HMS3652A16; HMS3713K13; HMS5082M14; KUC109573N; Pharmakon1600-01505974; CLOFAZIMINE [USP MONOGRAPH]; CLOFAZIMINUM [WHO-IP LATIN]; HY-B1046; KSC-27-052A; Tox21_110516; BDBM50318909; BDBM50378783; EBC-13571; MSK159113; NSC759283; s4107; AKOS015896438; AKOS026749881; Clofazimine for system suitability CRS; AC20496; CCG-101159; CCG-269477; CS-4567; DB00845; KS-1412; NC00409; NSC-759283; (3Z)-N,5-bis(4-chlorophenyl)-3-[(1-methylethyl)imino]-3,5-dihydrophenazin-2-amine; NCGC00016600-02; NCGC00016600-03; NCGC00016600-04; NCGC00016600-05; NCGC00016600-07; NCGC00016600-08; NCGC00016600-09; NCGC00179529-01; AC-38030; DA-72278; SMR004701474; Clofazimine 100 microg/mL in Acetonitrile; Phenazine,10-dihydro-2-(isopropylimino)-; SBI-0206865.P001; C2866; NS00011720; ST51014966; SW196840-4; C06915; D00278; EN300-267815; C458567; EN300-21680301; Q418611; SR-01000000259; SR-01000000259-6; SR-05000001807-1; SR-05000001807-2; BRD-K56614220-001-10-9; BRD-K56614220-001-18-2; BRD-K56614220-001-19-0; BRD-K56614220-001-21-6; Z2037279473; Clofazimine, European Pharmacopoeia (EP) Reference Standard; Clofazimine, United States Pharmacopeia (USP) Reference Standard; 2-p-Chloranilino-5-p-chlorphenyl-3,5-dihydro-3-isopropylimino-phenazin; (3E)-N,5-bis(4-chlorophenyl)-3-[(propan-2-yl)imino]-3,5-dihydrophenazin-2-amine; (4-Chloro-phenyl)-[5-(4-chloro-phenyl)-3-isopropylimino-3,5-dihydro-phenazin-2-yl]-amine; (E)-N,5-bis(4-chlorophenyl)-3-(isopropylimino)-3,5-dihydrophenazin-2-amine; 2-Phenazinamine,5-bis(4-chlorophenyl)-3,5-dihydro-3-[(1-methylethyl)imino]-; 2-Phenazinamine,5-dihydro-N,5-bis(4-chlorophenyl)-3-[(1-methylethyl)imino]-; Clofazimine for system suitability, European Pharmacopoeia (EP) Reference Standard; N,5-Bis(4-chlorophenyl)-3-([1-methylethyl]imino)-3,5-dihydro-2-phenazinamine #; Phenazine,10-dihydro-3-(p-chloroanilino)-10-(p-chlorophenyl)-2-(isopropylimino)-; (4-chlorophenyl)[5-(4-chlorophenyl)-3-(2-methyl-1-azapropylidene)(5-hydrophena zin-2-yl)]amine; 2458811-14-6別名